Prelude Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

PRLD$3.76+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity (Unaudited)

STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY

Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares)	Shares	Amount	Shares	Amount	capital	loss	deficit	Total
Balance at January 1, 2024	42,063,995	$4	12,850,259	$1	$693,252	$223	$(456,390)	$237,090
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 4,285 shares withheld for employee taxes	7,510	—	—	—	(14)	—	—	(14)
Unrealized loss on marketable securities, net of tax	—	—	—	—	—	(458)	—	(458)
Stock-based compensation expense	—	—	—	—	5,547	—	—	5,547
Net loss	—	—	—	—	—	—	(31,431)	(31,431)
Balance at March 31, 2024	42,071,505	$4	12,850,259	$1	$698,785	$(235)	$(487,821)	$210,734
Issuance of common stock upon exercise of stock options & vesting of RSU's, net of 3,722 shares withheld for employee taxes	7,803	—	—	—	(16)	—	—	(16)
Issuance of common stock under ESPP	78,916	—	—	—	255	—	—	255
Unrealized loss on marketable securities, net of tax	—	—	—	—	—	(55)	—	(55)
Stock-based compensation expense	—	—	—	—	6,098	—	—	6,098
Net loss	—	—	—	—	—	—	(34,740)	(34,740)
Balance at June 30, 2024	42,158,224	$4	12,850,259	$1	$705,122	$(290)	$(522,561)	$182,276
Issuance of common stock upon exercise of stock options & vesting of RSU's, net of 3,722 shares withheld for employee taxes	19,788	—	—	—	43	—	—	43
Unrealized gain on marketable securities	—	—	—	—	—	457	—	457
Stock-based compensation expense	—	—	—	—	5,926	—	—	5,926
Net loss	—	—	—	—	—	—	(32,271)	(32,271)
Balance at September 30, 2024	42,178,012	$4	12,850,259	$1	$711,091	$167	$(554,832)	$156,431

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)

Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares)	Shares	Amount	Shares	Amount	capital	loss	deficit	Total
Balance at January 1, 2023	36,496,994	$4	11,402,037	$1	$531,682	$(1,692)	$(334,558)	$195,437
Issuance of common stock upon exercise of stock options & vesting of RSUs	17,224	—	—	—	28	—	—	28
Unrealized gain on marketable securities, net of tax	—	—	—	—	—	1,294	—	1,294
Stock-based compensation expense	—	—	—	—	6,256	—	—	6,256
Net loss	—	—	—	—	—	—	(27,718)	(27,718)
Balance at March 31, 2023	36,514,218	$4	11,402,037	$1	$537,966	$(398)	$(362,276)	$175,297
Issuance of common stock and prefunded warrants, net of issuance costs of $2.6 million	5,312,978	—	1,448,222	—	110,423	—	—	110,423
Issuance of common stock upon exercise of stock options & vesting of RSU's	40,461	—	—	—	3	—	—	3
Issuance of common stock under ESPP	90,799	—	—	—	348	—	—	348
Unrealized loss on marketable securities, net of tax	—	—	—	—	—	(313)	—	(313)
Stock-based compensation expense	—	—	—	—	6,733	—	—	6,733
Net loss	—	—	—	—	—	—	(30,431)	(30,431)
Balance at June 30, 2023	41,958,456	$4	12,850,259	$1	$655,473	$(711)	$(392,707)	$262,060
Issuance of common stock upon vesting of RSU's, net of 3,609 shares withheld for employee taxes	7,016	—	—	—	(16)	—	—	(16)
Unrealized gain on marketable securities	—	—	—	—	—	106	—	106
Stock-based compensation expense, net of forfeitures of restricted stock awards	—	—	—	—	6,715	—	—	6,715
Net loss	—	—	—	—	—	—	(30,608)	(30,608)
Balance at September 30, 2023	41,965,472	$4	12,850,259	$1	$662,172	$(605)	$(423,315)	$238,257

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.